Leerink Swann Downgrades Omthera Pharmaceuticals (OMTH) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Stifel Nicolaus Downgrades Omthera Pharmaceuticals (OMTH) to Hold
May 29, 2013 6:42 AM EDTStifel Nicolaus downgraded Omthera Pharmaceuticals (NASDAQ: OMTH) from Buy to Hold.
For an analyst ratings summary and ratings history on Omthera Pharmaceuticals click here. For more ratings news on Omthera Pharmaceuticals click here.
Shares of Omthera Pharmaceuticals closed at $13.51 yesterday, with a 52 week range of $5.69-$13.75.... More
Piper Jaffray Downgrades Omthera Pharmaceuticals (OMTH) to Neutral
May 28, 2013 11:09 AM EDTPiper Jaffray downgraded Omthera Pharmaceuticals (NASDAQ: OMTH) from Overweight to Neutral.
For an analyst ratings summary and ratings history on Omthera Pharmaceuticals click here. For more ratings news on Omthera Pharmaceuticals click here.
Shares of Omthera Pharmaceuticals closed at $6.77 yesterday, with a 52 week range of $5.69-$7.90.... More
Omthera Pharmaceut (OMTH) Posts Q1 Loss of $3.08/Share
May 28, 2013 9:25 AM EDTOmthera Pharmaceut (NASDAQ: OMTH) reported Q1 EPS of ($3.08), $0.77 worse than the analyst estimate of ($2.31).
For earnings history and earnings-related data on Omthera Pharmaceut (OMTH) click here.... More
AstraZeneca (AZN) to Acquire Omthera (OMTH) for $12.70/Share
May 28, 2013 6:05 AM EDTAstraZeneca (NYSE: AZN) announced that it has entered into a definitive agreement to acquire Omthera Pharmaceuticals (Nasdaq: OMTH), a specialty pharmaceutical company based in Princeton, New Jersey, focused on the development and commercialisation of new therapies for abnormal levels of lipids in the blood, referred to as dyslipidemia.
Omtheras investigational product, EpanovaTM, for the potential treatment of patients with very high triglycerides, is a novel omega-3 free fatty acid composition that has been shown to bolster levels of eicosapentaenoic acid and docosahexaenoic acid... More
